ConductScience.org, home
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
API referenceFor AI assistants

Trial · NCT02852967

Results by group161

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 161

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 200 mg QD + PlaceboLOCF (%)8.795% Confidence Interval 1.1 to 28.0Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 200 mg BID (Twice Daily) + PlaceboLOCF (%)9.195% Confidence Interval 1.1 to 29.2Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 400 mg QD + PlaceboLOCF (%)19.095% Confidence Interval 5.4 to 41.9Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 600 mg/DayLOCF (%)7.795% Confidence Interval 0.9 to 25.1Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedPlaceboLOCF (%)16.795% Confidence Interval 3.6 to 41.4Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedAll BelumosudilLOCF (%)10.995% Confidence Interval 5.3 to 19.1Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 200 mg QD + PlaceboObserved (%)7.195% Confidence Interval 0.2 to 33.9Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 200 mg BID (Twice Daily) + PlaceboObserved (%)13.395% Confidence Interval 1.7 to 40.5Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 400 mg QD + PlaceboObserved (%)23.595% Confidence Interval 6.8 to 49.9Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedBelumosudil 600 mg/DayObserved (%)12.595% Confidence Interval 1.6 to 38.3Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedPlaceboObserved (%)30.095% Confidence Interval 6.7 to 65.2Percentage of participants
Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and ObservedAll BelumosudilObserved (%)14.595% Confidence Interval 6.9 to 25.8Percentage of participants
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 200 mg QD + PlaceboBaseline18.93Standard Deviation 8.31Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 200 mg BID (Twice Daily) + PlaceboBaseline20.60Standard Deviation 8.27Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 400 mg QD + PlaceboBaseline18.82Standard Deviation 6.08Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 600 mg/DayBaseline19.80Standard Deviation 9.03Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedPlaceboBaseline20.72Standard Deviation 8.08Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedAll BelumosudilBaseline19.55Standard Deviation 7.97Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 200 mg QD + PlaceboChange at Week 16--LOCF-5.69Standard Deviation 8.59Score on a scale
Efficacy: Mean Change of Raw PASI Score From Baseline to Week 16 and Week 48--LOCF and ObservedBelumosudil 200 mg BID (Twice Daily) + PlaceboChange at Week 16--LOCF-4.49Standard Deviation 7.44Score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02852967/results

API referenceFor AI assistants